Gilead fourth-quarter profit misses Wall Street estimate, shares fall

Gilead Sciences Inc on Monday reported fourth-quarter results that fell short of Wall Street estimates as sales of its flagship hepatitis C drugs continued to slide due to competition for a smaller pool of patients.